Rakovina Therapeutics Inc.

Rakovina Therapeutics Inc. is a biopharmaceutical research company dedicated to the development of innovative cancer treatments. Headquartered in Vancouver, British Columbia, Canada, the company's mission is to transform and extend the lives of cancer patients by advancing novel DNA-damage response (DDR) technologies. Rakovina leverages Artificial Intelligence (AI) to accelerate drug discovery and optimize potential drug candidates, aiming to bring new hope to those affected by cancer.

The company's core focus is on developing next-generation DDR inhibitors, utilizing proprietary AI platforms such as Deep Docking™ and Enki™ for efficient screening and optimization of molecular structures. Its pipeline includes several distinct programs: kt-2000AI, which focuses on AI-driven PARP1 inhibitors, including those designed for brain penetration; the kt-3000 series, comprising bi-functional small-molecule drug candidates that combine PARP and HDAC inhibition; and the kt-5000AI series, which develops AI-designed CNS-penetrant ATR inhibitors. These therapies target various cancers, including breast, ovarian, prostate, pancreatic, and brain tumors.

Recent activities include presenting new preclinical data at major scientific conferences, such as the AACR 2026 Annual Meeting and the 2025 Society for Neuro-Oncology Annual Meeting, highlighting the efficacy of its AI-discovered CNS-penetrant ATR/mTOR inhibitors and PARP1 inhibitors. Led by CEO Kim Oishi, President & Chief Scientific Officer Mads Daugaard, CFO David Kideckel, and Executive Chairman Jeffrey Bacha, Rakovina Therapeutics aims to advance its drug candidates into human clinical trials through collaborations with pharmaceutical partners and secure marketing approvals from regulatory agencies. The company emphasizes the transformative potential of AI in accelerating the drug discovery process.